TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice

Heather L. Clifton, Bora Inceoglu, Linlin Ma, Jie Zheng, Saul Schaefer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Niacin is effective in treating dyslipidemias but causes cutaneous vasodilation or flushing, a side effect that limits its clinical use. Blocking prostaglandins in humans reduces but does not consistently eliminate flushing, indicating additional mechanisms may contribute to flushing. The transient receptor potential vanilloid 1 (TRPV1) channel, when activated, causes cutaneous vasodilation and undergoes tachyphylaxis similar to that seen with niacin. Using a murine model, early phase niacin-induced flushing was examined and TRPV1 channel involvement demonstrated using pharmacologic blockade, desensitization, and genetic knockouts (TRPV1 KO). The TRPV1 antagonist AMG9810 reduced the magnitude of the initial and secondary peaks and the rapidity of the vasodilatory response (slope). TRPV1 desensitization by chronic capsaicin reduced the initial peak and slope. TRPV1 KO mice had a lower initial peak, secondary peak, and slope compared with wild-type mice. Chronic niacin reduced the initial peak, secondary peak, and slope in wild-type mice but had no effect in knockout mice. Furthermore, chronic niacin diminished the response to capsaicin in wild-type mice. Overall, these data demonstrate an important role for TRPV1 channels in niacin-induced flushing, both in the acute response and with chronic administration. That niacin-induced flushing is a complex cascade of events, which should inform pharmacological intervention against this side effect.

Original languageEnglish (US)
Pages (from-to)184-191
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume65
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Niacin
Vasodilation
Skin
Capsaicin
Tachyphylaxis
Dyslipidemias
vanilloid receptor subtype 1
Knockout Mice
Prostaglandins
Pharmacology

Keywords

  • cutaneous vasodilation
  • flushing
  • niacin
  • TRPV1 channels

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice. / Clifton, Heather L.; Inceoglu, Bora; Ma, Linlin; Zheng, Jie; Schaefer, Saul.

In: Journal of Cardiovascular Pharmacology, Vol. 65, No. 2, 2015, p. 184-191.

Research output: Contribution to journalArticle

Clifton, Heather L. ; Inceoglu, Bora ; Ma, Linlin ; Zheng, Jie ; Schaefer, Saul. / TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice. In: Journal of Cardiovascular Pharmacology. 2015 ; Vol. 65, No. 2. pp. 184-191.
@article{2cecd16cb1b94de092ad2a5dcad6a5ca,
title = "TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice",
abstract = "Niacin is effective in treating dyslipidemias but causes cutaneous vasodilation or flushing, a side effect that limits its clinical use. Blocking prostaglandins in humans reduces but does not consistently eliminate flushing, indicating additional mechanisms may contribute to flushing. The transient receptor potential vanilloid 1 (TRPV1) channel, when activated, causes cutaneous vasodilation and undergoes tachyphylaxis similar to that seen with niacin. Using a murine model, early phase niacin-induced flushing was examined and TRPV1 channel involvement demonstrated using pharmacologic blockade, desensitization, and genetic knockouts (TRPV1 KO). The TRPV1 antagonist AMG9810 reduced the magnitude of the initial and secondary peaks and the rapidity of the vasodilatory response (slope). TRPV1 desensitization by chronic capsaicin reduced the initial peak and slope. TRPV1 KO mice had a lower initial peak, secondary peak, and slope compared with wild-type mice. Chronic niacin reduced the initial peak, secondary peak, and slope in wild-type mice but had no effect in knockout mice. Furthermore, chronic niacin diminished the response to capsaicin in wild-type mice. Overall, these data demonstrate an important role for TRPV1 channels in niacin-induced flushing, both in the acute response and with chronic administration. That niacin-induced flushing is a complex cascade of events, which should inform pharmacological intervention against this side effect.",
keywords = "cutaneous vasodilation, flushing, niacin, TRPV1 channels",
author = "Clifton, {Heather L.} and Bora Inceoglu and Linlin Ma and Jie Zheng and Saul Schaefer",
year = "2015",
doi = "10.1097/FJC.0000000000000181",
language = "English (US)",
volume = "65",
pages = "184--191",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice

AU - Clifton, Heather L.

AU - Inceoglu, Bora

AU - Ma, Linlin

AU - Zheng, Jie

AU - Schaefer, Saul

PY - 2015

Y1 - 2015

N2 - Niacin is effective in treating dyslipidemias but causes cutaneous vasodilation or flushing, a side effect that limits its clinical use. Blocking prostaglandins in humans reduces but does not consistently eliminate flushing, indicating additional mechanisms may contribute to flushing. The transient receptor potential vanilloid 1 (TRPV1) channel, when activated, causes cutaneous vasodilation and undergoes tachyphylaxis similar to that seen with niacin. Using a murine model, early phase niacin-induced flushing was examined and TRPV1 channel involvement demonstrated using pharmacologic blockade, desensitization, and genetic knockouts (TRPV1 KO). The TRPV1 antagonist AMG9810 reduced the magnitude of the initial and secondary peaks and the rapidity of the vasodilatory response (slope). TRPV1 desensitization by chronic capsaicin reduced the initial peak and slope. TRPV1 KO mice had a lower initial peak, secondary peak, and slope compared with wild-type mice. Chronic niacin reduced the initial peak, secondary peak, and slope in wild-type mice but had no effect in knockout mice. Furthermore, chronic niacin diminished the response to capsaicin in wild-type mice. Overall, these data demonstrate an important role for TRPV1 channels in niacin-induced flushing, both in the acute response and with chronic administration. That niacin-induced flushing is a complex cascade of events, which should inform pharmacological intervention against this side effect.

AB - Niacin is effective in treating dyslipidemias but causes cutaneous vasodilation or flushing, a side effect that limits its clinical use. Blocking prostaglandins in humans reduces but does not consistently eliminate flushing, indicating additional mechanisms may contribute to flushing. The transient receptor potential vanilloid 1 (TRPV1) channel, when activated, causes cutaneous vasodilation and undergoes tachyphylaxis similar to that seen with niacin. Using a murine model, early phase niacin-induced flushing was examined and TRPV1 channel involvement demonstrated using pharmacologic blockade, desensitization, and genetic knockouts (TRPV1 KO). The TRPV1 antagonist AMG9810 reduced the magnitude of the initial and secondary peaks and the rapidity of the vasodilatory response (slope). TRPV1 desensitization by chronic capsaicin reduced the initial peak and slope. TRPV1 KO mice had a lower initial peak, secondary peak, and slope compared with wild-type mice. Chronic niacin reduced the initial peak, secondary peak, and slope in wild-type mice but had no effect in knockout mice. Furthermore, chronic niacin diminished the response to capsaicin in wild-type mice. Overall, these data demonstrate an important role for TRPV1 channels in niacin-induced flushing, both in the acute response and with chronic administration. That niacin-induced flushing is a complex cascade of events, which should inform pharmacological intervention against this side effect.

KW - cutaneous vasodilation

KW - flushing

KW - niacin

KW - TRPV1 channels

UR - http://www.scopus.com/inward/record.url?scp=84925537882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925537882&partnerID=8YFLogxK

U2 - 10.1097/FJC.0000000000000181

DO - 10.1097/FJC.0000000000000181

M3 - Article

C2 - 25387247

AN - SCOPUS:84925537882

VL - 65

SP - 184

EP - 191

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -